Diabetes

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Tuesday, January 31, 2017

Five things for pharma marketers to know: Tuesday, January 31, 2017

By

Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing

Five things for pharma marketers to know: Friday January 27, 2017

Five things for pharma marketers to know: Friday January 27, 2017

By

BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup

When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

By

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

Lexicon developing type 1 diabetes treatment with Sanofi

Lexicon developing type 1 diabetes treatment with Sanofi

By

Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.

Five things for pharma marketers to know: Wednesday, December 28, 2016

Five things for pharma marketers to know: Wednesday, December 28, 2016

By

Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

By

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

Eli Lilly will discount its insulins to some patients

Eli Lilly will discount its insulins to some patients

By

Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.

Five things for pharma marketers to know: Tuesday, December 13, 2016

Five things for pharma marketers to know: Tuesday, December 13, 2016

By

Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant

How Digital Innovation is Influencing Diabetes Care

How Digital Innovation is Influencing Diabetes Care

Adherence is one of the biggest challenges physicians face in diabetes management.

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

By

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

By

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Lilly's branded app for Trulicity looks to address adherence

Lilly's branded app for Trulicity looks to address adherence

By

Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

By

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

By

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

By

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Five things for pharma marketers to know: Tuesday, October 4, 2016

Five things for pharma marketers to know: Tuesday, October 4, 2016

By

J&J insulin pumps are at risk of hacking; Merrimack CEO leaves and cuts workforce; Japanese scientists wins Nobel

Five things for pharma marketers to know: Tuesday, September 27, 2016

Five things for pharma marketers to know: Tuesday, September 27, 2016

By

Amgen's Kyprolis fails to best Velcade in trial; diabetes drugs have lower than average FDA approval rate; Bayer's derm business draws interest

Ogilvy's Michael Johnston on Using the Familiar in Diabetes Ads

Ogilvy's Michael Johnston on Using the Familiar in Diabetes Ads

The science behind new diabetes drugs underscores how far we've come from the days of purified pork insulin. Even so, most ads stick to traditional copy.

Five things for pharma marketers to know: Monday, September 19, 2016

Five things for pharma marketers to know: Monday, September 19, 2016

By

Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study

Five things for pharma marketers to know: Monday, September 12, 2016

Five things for pharma marketers to know: Monday, September 12, 2016

By

Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

By

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

Infographic: Type 2 diabetes, a country-by-country snapshot

Infographic: Type 2 diabetes, a country-by-country snapshot

Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

By By

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

Five things for pharma marketers to know: Wednesday, June 15, 2016

Five things for pharma marketers to know: Wednesday, June 15, 2016

By

Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway

How a startup is educating kids with diabetes with a teddy bear

How a startup is educating kids with diabetes with a teddy bear

By

Sproutel CEO Aaron Horowitz talks about how Jerry the Bear came to life and why endocrinologists are stocking the bear in their offices.

OPINION

Newsletters